Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$7.50 USD
-0.11 (-1.45%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.49 -0.01 (-0.13%) 4:54 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SANA 7.50 -0.11(-1.45%)
Will SANA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SANA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SANA
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
SANA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
Other News for SANA
GFS, PETS and CYTK are among after hour movers
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Sana Biotechnology highlights publication in Nature Biotechnology
Commit To Purchase Sana Biotechnology At $5, Earn 21.2% Annualized Using Options
Bank of America Securities Remains a Buy on Sana Biotechnology (SANA)